Industry Veteran Peter Chambré Joins Cancer Research UK
Cancer Research UK has appointed Peter Chambré trustee. He is currently chair of various life sciences and healthcare companies including Immatics Biotechnologies and OneMed and chairs Cancer Research’s commercialization arm, Cancer Research Technology Ltd. (CRT). Chambré is also director of Spectris PLC and Imperial Innovations PLC and was previously CEO of Cambridge Antibody Technology PLC until its acquisition by AstraZeneca in 2006.
Register for our free email digests: